Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)

HKG:2315 Revenue

Biocytogen Pharmaceuticals (Beijing) had revenue of 461.37M CNY in the quarter ending September 30, 2026, with 44.22% growth. This brings the company's total for the last twelve months to 1.84B, up 38.25% year-over-year. In the year 2025, Biocytogen Pharmaceuticals (Beijing) had annual revenue of 1.38B with 40.63% growth. That makes Biocytogen Pharmaceuticals (Beijing) the 15,189th largest company in the world by revenue and 889th in Hong Kong.

• Revenue (ttm): 1.84B CNY
• Revenue Growth: +38.25%
• P/S Ratio: 16.60
• Revenue / Employee: 957.69K CNY
• Employees: 1,922
• Market Cap: 37.12B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Segment

By Segment

Chart

• Animal Models Selling 419.84M 41.5%
• Antibody Development 317.79M 31.4%
• Pre-Clinical Pharmacology and Efficacy Evaluation 200.99M 19.9%
• Gene Editing 72.08M 7.1%
• Others 383.00K 0.0%

By Geography

Chart

• The United States of America (USA) 494.39M 50.4%
• China 318.20M 32.5%
• Others 167.87M 17.1%

Fiscal year ended Dec 31, 2024 See the full HKG:2315 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.38B	398.35M	40.63%
Dec 31, 2024	980.45M	263.54M	36.76%
Dec 31, 2023	716.91M	183.03M	34.28%
Dec 31, 2022	533.88M	179.33M	50.58%
Dec 31, 2021	354.56M	101.01M	39.84%

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error